CD8A and myeloid sarcoma: To determine the effector function and activation status of CD8+ T cells ex vivo between different compartments of MS patients, expression of the death signal and co-stimulatory receptor FasL (CD95L) and the early activation marker CD137 were determined by multiplex flow cytometry on CD8+ T cells (Fig. 3a).